Guidance
Evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Get involved
We want you to be involved in our work. Tell us what matters to you, your organisation or your community.
There are many ways you can get involved as a healthcare professional or a member of the public.
About us
Find out more about
and how we support
The NICE strategy 2021 to 2026 sets out an ambitious vision for our future.
Latest news
-
More than 600 people could benefit from an innovative drug for a form of lung cancer as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund.
-
People with depression should make the choice on what treatment option is right for them, in discussion with their healthcare professional, NICE says in new draft guidance.
-
Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE today (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA).
-
NICE has today (18 November 2021) published draft guidance recommending the first long-acting injectable treatment for HIV-1 infection in adults.
Explore NICE
Into practice
Resources to help you use our guidance and quality standards
Financial planning
Advice and tools to help you make the best use of your resources
Antimicrobial resistance
View our antimicrobial prescribing guidelines
Our role in patient safety
Our guidelines make evidence-based, best practice recommendations.
Find journals and databases
Access to a range of journals and other evidence-based resources.